Anúncio
Anúncio
ADCT
ADC Therapeutics SA
3.66
USDPatrocinado
+0.09
+2.55%
09 de jan., 15:59 UTC -5
Encerrado
Pré-Mercado
3.73
+0.07
+1.91%
Relatórios de Lucros ADCT
Rácio de surpresa positiva
ADCT separação 13 de 22 últimas estimativas.
59%
Próximo Relatório
Data do Próximo Relatório
25 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$18.70M
/-$0.29
Mudanças implicadas de Q3 25 (Revenue/ EPS)
+13.81%
/-3.33%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
+10.56%
/+3.57%
ADC Therapeutics SA earnings per share and revenue
On 10 de nov. de 2025, ADCT reported earnings of -0.30 USD per share (EPS) for Q3 25, beating the estimate of -0.36 USD, resulting in a 18.68% surprise. Revenue reached 16.43 milhão, compared to an expected 17.42 milhão, with a -5.69% difference. The market reacted with a +4.21% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 8 analistas forecast an EPS of -0.29 USD, with revenue projected to reach 18.70 milhão USD, implying an diminuir of -3.33% EPS, and aumentar of 13.81% in Revenue from the last quarter.
FAQ
What were ADC Therapeutics SA's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, ADC Therapeutics SA reported EPS of -$0.30, beating estimates by 18.68%, and revenue of $16.43M, -5.69% below expectations.
How did the market react to ADC Therapeutics SA's Q3 2025 earnings?
The stock price moved up 4.21%, changed from $4.04 before the earnings release to $4.21 the day after.
When is ADC Therapeutics SA expected to report next?
The next earning report is scheduled for 25 de mar. de 2026.
What are the forecasts for ADC Therapeutics SA's next earnings report?
Based on 8
analistas, ADC Therapeutics SA is expected to report EPS of -$0.29 and revenue of $18.70M for Q4 2025.
Which companies are reporting earnings today?
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio